Myeloperoxidase-Dependent LDL Modifications in Bloodstream Are Mainly Predicted by Angiotensin II, Adiponectin, and Myeloperoxidase Activity: A Cross-Sectional Study in Men
Zouaoui Boudjeltia, Karim; Delporte, Cédric; Van Antwerpen, Pierreet al.
[en] The present paradigm of atherogenesis proposes that low density lipoproteins (LDLs) are trapped in subendothelial space of the vascular wall where they are oxidized. Previously, we showed that oxidation is not restricted to the subendothelial location. Myeloperoxidase (MPO), an enzyme secreted by neutrophils and macrophages, can modify LDL (Mox-LDL) at the surface of endothelial cells. In addition we observed that the activation of the endothelial cells by angiotensin II amplifies this process. We suggested that induction of the NADPH oxidase complex was a major step in the oxidative process. Based on these data, we asked whether there was an independent association, in 121 patients, between NADPH oxidase modulators, such as angiotensin II, adiponectin, and levels of circulating Mox-LDL. Our observations suggest that the combination of blood angiotensin II, MPO
activity, and adiponectin explains, at least partially, serum Mox-LDL levels.
Research Center/Unit :
CORD - Centre de l'Oxygène, Recherche et Développement - ULiège
Disciplines :
Urology & nephrology
Author, co-author :
Zouaoui Boudjeltia, Karim; Université Libre de Bruxelles - ULB > Laboratory of Experimental Medicine (ULB 222 Unit)
Delporte, Cédric; Université Libre de Bruxelles - ULB > Laboratory of Pharmaceutical Chemistry and Analytical Platform
Van Antwerpen, Pierre; Université Libre de Bruxelles - ULB > Laboratory of Pharmaceutical Chemistry and Analytical Platform
Serteyn, Didier ; Université de Liège - ULiège > Département clinique des animaux de compagnie et des équidés > Anesthésiologie gén. et pathologie chirurg. des grds animaux
Moguilevsky, Nicole; Facultés Universitaires Notre-Dame de la Paix - Namur - FUNDP > Technology Transfer Office,
Raes, Martine; Université Libre de Bruxelles - ULB > Laboratory of Biochemistry and Cellular Biology (NARILIS)
Vanhamme, Luc; Université Libre de Bruxelles - ULB > Institute for Molecular Biology and Medicine (IBMM),
Vanhaeverbeek, Michel; Université Libre de Bruxelles - ULB > Laboratory of Experimental Medicine (ULB 222 Unit)
Van Meerhaeghe, Alain; Université Libre de Bruxelles - ULB > Laboratory of Experimental Medicine (ULB 222 Unit)
Roumeguère, Thierry; Université Libre de Bruxelles - ULB > Department of Urology, Erasme University Hospital
Language :
English
Title :
Myeloperoxidase-Dependent LDL Modifications in Bloodstream Are Mainly Predicted by Angiotensin II, Adiponectin, and Myeloperoxidase Activity: A Cross-Sectional Study in Men
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Lind L., Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003 169 2 203 214 2-s2.0-0142061128 10.1016/S0021-9150(03) 00012-1 (Pubitemid 37297466)
Noels H., Weber C., catching up with important players in atherosclerosis: type i interferons and neutrophils. Current Opinion in Lipidology 2011 22 2 144 145
Weber C., Noels H., Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine 2011 17 11 1410 1422 2-s2.0-81255188900 10.1038/nm.2538
Klebanoff S. J., Myeloperoxidase: friend and foe. Journal of Leukocyte Biology 2005 77 5 598 625 2-s2.0-18244390487 10.1189/jlb.1204697 (Pubitemid 40628741)
Daugherty A., Dunn J. L., Rateri D. L., Heinecke J. W., Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. Journal of Clinical Investigation 1994 94 1 437 444 2-s2.0-0028292033 (Pubitemid 24218123)
Malle E., Marsche G., Arnhold J., Davies M. J., Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochimica et Biophysica Acta 2006 1761 4 392 415 2-s2.0-33646826643 10.1016/j.bbalip.2006.03.024 (Pubitemid 43776460)
Davies M. J., Hawkins C. L., Pattison D. I., Rees M. D., Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxidants and Redox Signaling 2008 10 7 1199 1234 2-s2.0-43049173503 10.1089/ars.2007.1927 (Pubitemid 351634397)
Delporte C., Franck T., Noyon C., Simultaneous measurement of protein-bound 3-chlorotyrosine and homocitrulline by LC-MS/MS after hydrolysis assisted by microwave: application to the study of myeloperoxidase activity during hemodialysis. Talanta 2012 99 603 609
Zouaoui Boudjeltia K., Moguilevsky N., Legssyer I., Babar S., Guillaume M., Delree P., Vanhaeverbeek M., Brohee D., Ducobu J., Remacle C., Oxidation of low density lipoproteins by myeloperoxidase at the surface of endothelial cells: an additional mechanism to subendothelium oxidation. Biochemical and Biophysical Research Communications 2004 325 2 434 438 2-s2.0-7644235262 10.1016/j.bbrc.2004.10.049 (Pubitemid 39458014)
Boudjeltia K., Faraut B., Esposito M. J., Stenuit P., Dyzma M., van Antwerpen P., Brohée D., vanhamme L., Moguilevsky N., Vanhaeverbeek M., Kerkhofs M., Temporal dissociation between myeloperoxidase (MPO)-modified LDL and MPO elevations during chronic sleep restriction and recovery in healthy young men. PLoS ONE 2011 6 11 2-s2.0-82355183889 10.1371/journal.pone.0028230 e28230
Higuchi S., Ohtsu H., Suzuki H., Shirai H., Frank G. D., Eguchi S., Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clinical Science 2007 112 7-8 417 428 2-s2.0-34247113814 10.1042/CS20060342 (Pubitemid 46587457)
Roberto C., Pasquale P., Serena D. S., Simona B., Valerio S., Laura N., Gaetano T., Stefania B., Francesco V., Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis 2010 213 1 225 234 2-s2.0-77958486858 10.1016/j.atherosclerosis.2010.08.056
Roumeguére T., Boudjeltia K. Z., Hauzeur C., Schulman C., Vanhaeverbeek M., Wespes E., Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU International 2009 104 4 511 517 2-s2.0-69849087363 10.1111/j.1464-410X.2009.08418.x
Franck T., Kohnen S., Boudjeltia K. Z., van Antwerpen P., Bosseloir A., Niesten A., Gach O., Nys M., Deby-Dupont G., Serteyn D., A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. Talanta 2009 80 2 723 729 2-s2.0-70349978312 10.1016/j.talanta.2009.07.052
Delporte C., van Antwerpen P., Vanhamme L., Roumeguere T., Zouaoui Boudjeltia K., Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediators Inflammation 2013 2013 18 971579 10.1155/2013/971579
Vaes M., Boudjeltia K. Z., van Antwerpen P., Low-density lipoprotein oxidation by myeloperoxidase occurs in the blood circulation during hemodialysis. Atherosclerosis 2006 7 3 Proceedings of the 4th international symposium on Th-P15:146 525
Li H., Cao Z., Moore D. R., Microbicidal activity of vascular peroxidase 1 in human plasma via generation of hypochlorous acid. Infection and Immunity 2012 80 7 2528 2537 10.1128/IAI.06337-11
Shi R., Hu C., Yuan Q., Yang T., Peng J., Li Y., Bai Y., Cao Z., Cheng G., Zhang G., Involvement of vascular peroxidase 1 in angiotensin II-induced vascular smooth muscle cell proliferation. Cardiovascular Research 2011 91 1 27 36 2-s2.0-79958836580 10.1093/cvr/cvr042
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
